12:00 AM
 | 
May 08, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

105AD7: Began Phase I/II testing

Onyvax Ltd., London, U.K.
Product: 105AD7
Business: Cancer
Therapeutic category: Immune stimulation
Target: Immune cells
Description: Anti-idiotype antibody vaccine...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >